Hormonal
FGF15/19 acts as an endocrine hormone to repress hepatic gluconeogenesis and stimulate glycogen synthesis, functioning as a post-prandial signal that complements insulin.
This paper describes FGF15/19 as a natural hormone released after eating that helps store energy as glycogen and stops the liver from making new glucose. It works alongside insulin but has its own unique pathway. For practical purposes, this highlights the importance of the post-meal state in metabolic health, though no specific intervention is prescribed.
FGF15/19 represses gluconeogenesis by inhibiting the activity of the transcription factor CREB... FGF19 increased hepatic glycogen synthase activity by inducing the phosphorylation and inactivation of glycogen synthase kinase 3a and 3b... Thus, FGF15/19 acts after insulin in the transition from the fed to the fasted state.
Why this rating
Based on multiple mouse knockout and transgenic studies with consistent findings, though human data is observational/correlational.
Source
Endocrine fibroblast growth factors 15/19 and 21: from feast to famine
Matthew J. Potthoff et al. · Genes & Development · 2012
DOI 10.1101/gad.184788.111
More from this paper
- FGF21 is induced by fasting and acts as a glucagon-like hormone to promote ketogenesis, gluconeogenesis, and fatty acid oxidation during starvation.Good
- Pharmacological administration of FGF21 improves insulin sensitivity, reduces hepatic triglycerides, and causes weight loss in obese rodents and primates.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →